Literature DB >> 11555708

Diffuse large cell lymphoma.

B Coiffier1.   

Abstract

A review of new or emerging ideas concerning diffuse large B-cell lymphomas is presented, with particular emphasis on histologic classification, genetic prognostic factors, first-line and salvage treatments, and specific locations such as neurologic, cutaneous, or gastrointestinal sites. This lymphoma remains the most heterogeneous of all lymphomas for its clinical characteristics and outcome. This heterogeneity is probably secondary to the fact that a large proportion of lymphomas seems to occur from a transformation of an unknown indolent lymphoma.

Entities:  

Mesh:

Year:  2001        PMID: 11555708     DOI: 10.1097/00001622-200109000-00003

Source DB:  PubMed          Journal:  Curr Opin Oncol        ISSN: 1040-8746            Impact factor:   3.645


  47 in total

1.  Primary diffuse large B-cell lymphoma of the oral cavity: germinal center classification.

Authors:  Indraneel Bhattacharyya; Hardeep K Chehal; Donald M Cohen; Samer Z Al-Quran
Journal:  Head Neck Pathol       Date:  2010-06-09

2.  Classification of diffuse large B-cell lymphoma by immunohistochemistry demonstrates that elderly patients are more common in the non-GC subgroup and younger patients in the GC subgroup.

Authors:  Ulf Thunberg; Gunilla Enblad; Mattias Berglund
Journal:  Haematologica       Date:  2012-02       Impact factor: 9.941

3.  Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis.

Authors:  Tri K Nguyen; Nicholas Jordan; Jonathan Friedberg; Richard I Fisher; Paul Dent; Steven Grant
Journal:  Leuk Res       Date:  2010-02-01       Impact factor: 3.156

4.  Efficacy and safety of rituximab combined with chemotherapy in the treatment of diffuse large B-cell lymphoma: a meta-analysis.

Authors:  Fanlu Meng; Diansheng Zhong; Linlin Zhang; Yi Shao; Qing Ma
Journal:  Int J Clin Exp Med       Date:  2015-10-15

5.  Evaluation of AKT phosphorylation and PTEN loss and their correlation with the resistance of rituximab in DLBCL.

Authors:  Yihui Ma; Pengyu Zhang; Yi Gao; Huijie Fan; Mingzhi Zhang; Jingjing Wu
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

Review 6.  [DNA-chips in the diagnosis of hematological malignancies].

Authors:  M Feuring-Buske; E M Hartmann; G Ott; H Reuter; C Buske; A Rosenwald
Journal:  Internist (Berl)       Date:  2006-01       Impact factor: 0.743

Review 7.  CD10 expression in diffuse large B-cell lymphomas does not influence survival.

Authors:  Bettina Fabiani; Alain Delmer; Eric Lepage; Catherine Guettier; Tony Petrella; Josette Brière; Anne-Marie Penny; Marie-Christine Copin; Jacques Diebold; Felix Reyes; Philippe Gaulard; Thierry J Molina
Journal:  Virchows Arch       Date:  2004-10-27       Impact factor: 4.064

8.  Lack of prognostic significance of the germinal-center phenotype in diffuse large B-cell lymphoma patients treated with CHOP-like chemotherapy with and without rituximab.

Authors:  Ivana Ilić; Zdravko Mitrović; Igor Aurer; Sandra Bašić-Kinda; Ivo Radman; Radmila Ajduković; Boris Labar; Snježana Dotlić; Marin Nola
Journal:  Int J Hematol       Date:  2009-06-03       Impact factor: 2.490

Review 9.  Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.

Authors:  Rosalba Camicia; Hans C Winkler; Paul O Hassa
Journal:  Mol Cancer       Date:  2015-12-11       Impact factor: 27.401

10.  MicroRNA-23a expression in paraffin-embedded specimen correlates with overall survival of diffuse large B-cell lymphoma.

Authors:  Wan-ling Wang; Cui Yang; Xiao-lin Han; Ran Wang; Yan Huang; You-mei Zi; Jing-dong Li
Journal:  Med Oncol       Date:  2014-03-22       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.